A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects

PURPOSE: ABP 980 (KANJINTI(™)) is a biosimilar to reference product HERCEPTIN(®) (trastuzumab RP). The goal of this study was to characterize the safety, tolerability, and immunogenicity of ABP 980 plus pertuzumab (PERJETA(®)) when co-administered in a single infusion bag in healthy subjects. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanes, Vladimir, Chow, Vincent, Stewart, Tina, Puri, Adeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484235/
https://www.ncbi.nlm.nih.gov/pubmed/34355250
http://dx.doi.org/10.1007/s00280-021-04334-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484235/
https://www.ncbi.nlm.nih.gov/pubmed/34355250
http://dx.doi.org/10.1007/s00280-021-04334-x

Ejemplares similares